Caption Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Caption Management’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-4,065	Closed	-$99K	–	1459
2024 Q2	$75.9K	Sell	4,065 -1,935	-32%	-$36.3K	﹤0.01%	1038
2024 Q1	$118K	Buy	+6,000	New	+$117K	﹤0.01%	1042
2022 Q3	–	Sell	-1,184	Closed	-$13.5K	–	1686
2022 Q2	$11K	Sell	1,184 -64,439	-98%	-$601K	﹤0.01%	1380
2022 Q1	$651K	Buy	65,623 +64,358	+5,088%	+$682K	0.01%	1095
2021 Q4	$14K	Sell	1,265 -16,235	-93%	-$200K	﹤0.01%	1530
2021 Q3	$199K	Buy	17,500 +5,500	+46%	+$71.6K	﹤0.01%	1348
2021 Q2	$168K	Sell	12,000 -22,340	-65%	-$339K	﹤0.01%	1192
2021 Q1	$635K	Buy	+34,340	New	+$702K	0.01%	767
2020 Q4	–	Sell	-7,500	Closed	-$132K	–	1131
2020 Q3	$116K	Buy	+7,500	New	+$141K	﹤0.01%	943

Other funds holding KNSA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Caption Management's KNSA Position: Q3 2024 in Review

Caption Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2024, closing a stake of 4,065 shares — an estimated $99K sold.

Caption Management first reported a position in KNSA in Q3 2020 and held it in 9 quarters. The position peaked at $651K in Q1 2022. 176 funds tracked by Wall St. Rank hold KNSA as of Q3 2024.

Caption Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Caption Management sold 4,065 Kiniksa Pharmaceuticals shares in Q3 2024, an estimated $99K.
Caption Management first reported a position in Kiniksa Pharmaceuticals in Q3 2020 and held it in 9 quarters.
Caption Management's Kiniksa Pharmaceuticals position peaked at $651K in Q1 2022.
176 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2024.

Based on Caption Management's 13F filing for Q3 2024, filed 14 Nov 2024.